Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Combivent Respimat Acceptability in COPD
NCT01019694Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Nov 2009
- Primary completion
- Apr 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of ipratropium bromide, salbutamol in chronic obstructive pulmonary disease (COPD), sponsored by Boehringer Ingelheim. Started Nov 2009; status: completed.
02
Drugs
ipratropium bromidesalbutamol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT01019694.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01019694.